Celularity Inc. Form 4 shows immediate vesting of 3,699 RSUs

Rhea-AI Filing Summary

Celularity Inc. (CELU) reported a new equity grant to a director. On 11/19/2025, the reporting person, who serves as a director of Celularity, received 3,699 shares of Class A common stock in the form of restricted stock units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan.

Each RSU represents a right to receive one share of Celularity's Class A common stock, and the RSUs vest and become exercisable on the date of grant. After this transaction, the director beneficially owns 3,699 Class A common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LeVien Vincent

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	3,699	$0.00	--

Holdings After Transaction: Class A Common Stock — 3,699 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeVien Vincent

(Last) (First) (Middle)

C/O CELULARITY INC.

170 PARK AVENUE

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Celularity Inc [ CELU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/19/2025		A		3,699(1)	A	$0.00	3,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the date of grant.

	/s/ Vincent LeVien	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Celularity Inc. (CELU) disclose in this Form 4?

The filing shows that a Celularity Inc. director received 3,699 restricted stock units (RSUs) of Class A common stock on 11/19/2025 under the company’s 2021 Equity Incentive Plan.

What do the 3,699 RSUs granted by Celularity Inc. (CELU) represent?

Each RSU represents a right to receive one share of Celularity’s Class A common stock, so 3,699 RSUs correspond to 3,699 Class A shares if and when settled.

When do the Celularity (CELU) RSUs granted on 11/19/2025 vest?

The filing states that the RSUs vest and become exercisable on the date of grant, meaning they vest immediately on 11/19/2025.

What price did the Celularity (CELU) director pay for the 3,699 RSUs?

The transaction table lists a price of $0.00 per share, indicating the RSUs were granted as compensation rather than purchased for cash.

How many Celularity (CELU) shares does the director own after this RSU grant?

After the reported transaction, the director beneficially owns 3,699 shares of Celularity’s Class A common stock directly.

Under which plan were the Celularity (CELU) RSUs granted?

The RSUs were granted under the Celularity Inc. 2021 Equity Incentive Plan, as disclosed in the explanation of responses.